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Abstract: Identification of 108 genomic regions significantly associated with schizophrenia risk
by the Psychiatric Genomics Consortium was a milestone for the field, and much work is now
focused on determining the mechanism of risk associated with each locus. Within these regions,
we investigated variability of DNA methylation, a low-level cellular phenotype closely linked to
genotype, in two highly similar cellular populations sampled from the human hippocampus, to draw
inferences about the elaboration of genotype to phenotype within these loci enriched for schizophrenia
risk. DNA methylation was assessed with the Illumina HumanMethylation450 BeadArray in tissue
laser-microdissected from the stratum oriens of subfield CA1 or CA2/3, regions having unique
connectivity with intrinsic and extrinsic fiber systems within the hippocampus. Samples consisted of
postmortem human hippocampus tissue from eight schizophrenia patients, eight bipolar disorder
patients, and eight healthy control subjects. Within these genomic regions, we observed far greater
difference in methylation patterns between circuit locations within subjects than in a single subregion
between subjects across diagnostic groups, demonstrating the complexity of genotype to phenotype
elaboration across the diverse circuitry of the human brain.
Keywords: DNA methylation; HumanMethylation450; schizophrenia; bipolar disorder; postmortem
human brain; epigenetics; hippocampus
1. Introduction
Recent years have brought exciting advances in our understanding of the genetic underpinnings of
major mental illnesses with the progress of next-generation sequencing technologies and bioinformatic
methods for analysis of the complex datasets they produce. The identification of 108 genome-wide
significant schizophrenia associated genomic regions by the Psychiatric Genomics Consortium (PGC)
in 2014 brought robust results from the field’s considerable investment into genome-wide association
studies, although now with these regions in hand the quest to understand this debilitating disorder is
of course still far from complete. These regions span more than 20 megabases of DNA (20877196 base
pairs [1]), approximately two thirds the size of the entire human exome [2], and are estimated to confer
only 3.4% of the variance in schizophrenia risk [3], leaving the bulk of disease liability still unexplained.
Schizophrenia is a neurodevelopmental disorder that likely involves molecular pathologies
throughout the vastly complex system of the human brain, shaped by genetic and environmental
influences spanning the time from early development throughout the lifespan [4]. Genotype is the
foundation from which the multitude of phenotypes expressed in any single cell (the epigenome,
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transcriptome, spliceosome, proteome, and so on) are elaborated through interaction with
environmental [5] and stochastic factors [6] that are not as yet fully understood. In the central
nervous system, phenotypes of single neurons or glia interact at the levels of cell types, individual
regions and larger networks of regions to produce the phenotype of the entire individual, from which
a complex syndrome such as schizophrenia or bipolar disorder may be displayed. In the context of the
daunting complexity presented by these and other neuropsychiatric disorders whose pathology lies
within the brain, it is pertinent to consider what the significance of disease-associated single nucleotide
polymorphisms (SNPs) identified in peripheral tissues such as blood may be.
It is likely that epigenetic mechanisms play an important role during brain development and
throughout the life cycle in defining the ways in which an individual’s genotype is expressed as
unique molecular phenotypes within specific neuronal subtypes in subregions of the brain. With the
goal of accessing this process occurring within the central nervous system, specific DNA methylation
signatures have been suggested as biomarkers of disease in peripheral blood that may have utility
in clinical diagnosis or treatment, but more work is needed before meaningful constructs emerge [7].
The utility of biomarkers of this type is complicated by the fact that DNA methylation patterns show
more variance between separate tissues as well as subregions within the brain of a single individual
than they do between a single subregion across multiple subjects. This has been reported for peripheral
blood mononuclear cells as compared to multiple human brain regions [8,9].
Many groups are now working to investigate the mechanisms conferring risk associated with
each PGC region, and DNA methylation is one potential mechanism of risk receiving a great deal of
attention. Methylation quantitative trait loci (meQTLs) are genomic regions where the DNA sequence
influences methylation of a region or regions of DNA in cis or in trans [10], and this effect may
be specific to distinct cell or tissue types and developmental time periods. Two important recent
studies [11,12] investigated postmortem human brain tissue across the lifespan to demonstrate that
PGC regions are enriched for sites that are differentially methylated between pre- and post-natal
life. Also, it was discovered that nearly 60% of PGC regions contain a significant meQTL, potentially
contributing to those regions’ mechanisms of risk. These studies analyzed samples of homogenized
whole cortex, and changes in DNA methylation across development were found to be related to
shifting proportions of different cellular populations within the brain [11]. Also, while the first study
investigated only dorsolateral prefrontal cortex in adult brain, the second compared three regions
(prefrontal cortex, striatum, and cerebellum) and found that while most fetal meQTLs were stable,
there were meQTLs that showed specificity with regard to time and brain region [12].
In light of these recent findings, we sought to investigate the variability of DNA methylation
patterns within the 108 PGC regions across closely related circuit locations within the human
hippocampus, and how this differs within and between individuals and diagnostic groups. The work
described herein is a focused secondary analysis of a previously reported investigation of DNA
methylation patterns in two distinct but highly similar cell populations sampled from hippocampal
subregions CA1 and CA2/3 [13]. These subregions were sampled from a cohort of 24 postmortem
human hippocampus tissue samples obtained from eight schizophrenia (SZ) patients, eight bipolar
disorder (BD) patients, and eight healthy control (CON) subjects. Laser microdissection was used to
dissect tissue specifically from the stratum oriens, the outermost cellular layer of the hippocampal
formation containing exclusively GABAergic interneurons as well as supportive non-neuronal cell
types [14], from subfields CA2/3 and CA1, the locations of the second and third synapses within the
trisynaptic pathway, respectively. DNA methylation was assessed in each of the 48 samples using
the Illumina HumanMethylation450 BeadArray, and the analysis was restricted to the 5476 probes
assessing cytosine residues found within the 108 PGC regions. Consistent with prior studies [8],
our results demonstrate greater differences in methylation patterns between circuit locations within
individuals than between single circuit locations across diagnostic groups. These data reinforce the
difficulty of extrapolating genetic signals to phenotypic events across distinct tissues, and showcase one
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aspect of heterogeneity within the brain that cannot be appreciated through measurements performed
in homogenized whole brain structures or in peripheral tissues.
2. Materials and Methods
2.1. Postmortem Human Hippocampus Tissue Samples
This work investigated a previously described [13] cohort containing postmortem human
hippocampus tissue samples from 24 individuals, eight with schizophrenia, eight with bipolar disorder,
and eight healthy controls, obtained from the Harvard Brain Tissue Resource Center (Table 1). Groups
were matched for gender, age, postmortem interval, and tissue pH. All cases were obtained through
family referral, not through the office of a medical examiner, and cases with documented history of
serious drug abuse were excluded.
On arrival to the center, the fresh brains were dissected and the hippocampus was removed and
sectioned. Tissue blocks used in this study were taken from the level of the pulvinar thalami along
the rostro-caudal axis of the hippocampus. Upon removal, tissue blocks were fixed in ice-cold 0.1%
formalin in 0.1 M phosphate buffer (pH 7.2) for 90 min before cryoprotection with 30% sucrose in
phosphate buffer overnight and then stored at −80 ◦C.
Table 1. Summary of demographic measures within the cohort.
Diagnosis n Gender Age PMI pH
CON 8 4M/4F 64.1 ± 14.2 22.4 ± 5.7 6.4 ± 0.2
SZ 8 4M/4F 67.9 ± 17.3 26.4 ± 10.3 6.4 ± 0.2
BD 8 3M/5F 68.3 ± 11.7 25.0 ± 6.7 6.3 ± 0.2
p 0.86 0.82 0.58 0.46
Demographic variables averaged within each diagnostic subgroup of the cohort are listed, with p values
for each measure generated by ANOVA provided in the final row. Full details for individual subjects are
available in a previous description of this cohort [13]. CON: control; SZ: schizophrenia; BD: bipolar disorder;
PMI: postmortem interval.
2.2. Sample Processing and DNA Methylation Measurement
Tissue blocks were embedded in Optimal Cutting Temperature compound (Sakura Finetek,
Torrance, CA, USA) and cut to 30 µm at 20 ◦C in a Microm HM560 cryostat. Sections were mounted on
polyethylene terephthalate frame slides (Leica, Wetzlar, Germany), Nissl stained and dehydrated with
ascending concentrations of ethanol. Sections were dried and stratum oriens tissue was dissected from
CA1 and from CA2/3 using a Leica LMD6500 laser microdissection system. DNA was extracted from
each sample using the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) and stored at −80 ◦C.
500 ng of genomic DNA was bisulfite modified using the EZ DNA Methylation Kit
(Zymo Research, Irvine, CA, USA) using modified parameters recommended by Illumina, and modified
DNA was assessed using the Illumina HumanMethylation450 BeadArray (Illumina, San Diego, CA,
USA) as per the manufacturer’s protocol.
2.3. Data Analysis
Data was analyzed within R version 3.3.2. (R Foundation, Vienna, Austria). Raw intensity idat files
were read into the minfi Bioconductor package [15] and whole-array data was normalized by stratified
quantile normalization. No samples were identified as outliers and all samples were included in the
analysis. M values (logit transformed β values which represent methylation ratios between 0 and 1)
were extracted and then the dataset was restricted to the 5476 probes assessing cytosine residues
within the original 128 genomic regions reported by the PGC [1]. Differentially methylated positions
(DMPositions) were identified with false detection rate (FDR) < 0.05 using linear regression with the
DMRCate Bioconductor package’s “myannotation” function [16] controlling for case (in comparisons
across regions within individual subjects), age, and postmortem interval (PMI). Differentially
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methylated regions (DMRegions) were identified with Stouffer corrected p value < 0.05 with the
“dmrcate” function within the DMRCate Bioconductor package, again with case (in comparisons across
regions within individual subjects), age, and PMI included as covariates.
3. Results
3.1. Differentially Methylated Positions
The Illumina HumanMethylation450 BeadArray was used to investigate diagnosis associated
changes in DNA methylation within the 108 PGC schizophrenia associated genomic regions in
postmortem human hippocampus tissue from schizophrenia, bipolar disorder, and healthy control
subjects. Investigation of the data for DMPositions identified only a single significant diagnosis
associate difference among all four comparisons (5476 probes compared between SZ CA1 and CON
CA1, SZ CA2/3 and CON CA2/3, BD CA1 and CON CA1, and BD CA2/3 and CON CA2/3). In the
SZ CA2/3 vs. CON CA2/3 comparison, probe cg07925823 within the first exon of the SLC7A6 gene on
chromosome 16 was significantly different between groups with FDR = 6.2 × 10−3.
Assessment of differences between circuit locations, on the other hand, identified 497 DMPositions
among all three comparisons (5476 probes compared between SZ CA1 and SZ CA2/3, BD CA1 and BD
CA2/3, and CON CA1 and CON CA2/3) (Figure 1a, Table 2 and Supplementary Materials file), and
966 DMPositions between CA1 and CA2/3 by pooling all 24 cases without consideration of diagnostic
categories (Figure 1b and Supplementary Materials file). In Figure 1a, it is apparent that DMPositions
within and between diagnostic groups cluster around certain genomic loci, generating the loosely
columnar appearance of the plot. More than 50% of individual probes corresponding to circuit location
DMPositions were shared between separate diagnostic subgroup comparisons, and 95% to 99% of
individual DMPositions identified in circuit location comparisons within diagnostic subgroups were
also identified as DMPositions in the pooled analysis (Table 2).
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Figure 1. Differentially Methylated Positions (DMPositions) in CA1 vs. CA3. (a) Shown are the
DMPositions identified within each eight-case diagnostic subgroup comparison (210 in SZ CA1 vs. SZ
CA2/3, 201 in BD CA1 vs. BD CA2/3, 86 in CON CA1 vs. CON CA2/3) with genomic location within
the space corresponding to the 5476 HM450 probes assessing sites within the original 128 PGC regions
(5476 probes within those regions ordered from chromosome 1 to chromosome X, p to q) depicted on
the X axis, and the −log10(FDR) on the Y axis. X-axis ticks mark the boundaries between PGC regions.
As seen by the loose vertical columns, the DMPositions from separate diagnostic subgroups have a high
degree of overlap, which is detailed in Table 2; (b) The 966 DMPositions identified in the pooled analysis
of all 24 CA1 samples vs. all 24 CA2/3 samples are depicted within the same X and Y axes as Figure 1a.
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Table 2. Distribution and overlap of differentially methylated positions among diagnosis and circuit
location comparisons.
Comparison # of DMPs Mean Delta Beta Mean FDR
SZ CA1 vs. SZ CA2/3 210 0.064 0.025
BD CA1 vs. BD CA2/3 201 0.063 0.023
CON CA1 vs. CON CA2/3 86 0.075 0.034
Pooled Cases CA1 vs. CA2/3 966 0.035 0.0087
SZ CA2/3 vs. CON CA2/3 1 0.035 0.0062
SZ CA1 vs. CON CA1 0 NA NA
BD CA2/3 vs. CON CA2/3 0 NA NA
BD CA1 vs. CON CA1 0 NA NA
Comparison # of DMPs % of DMPs
SZ vs. BD 107 53.23
SZ vs. CON 53 61.63
BD vs. CON 59 68.6
All 3 Groups 46 53.49
SZ vs. Pooled 199 94.76
BD vs. Pooled 195 97.01
CON vs. Pooled 85 98.83
All vs. Pooled 46 100
At the top are listed the number of DMPositions identified in each circuit location (i.e., SZ CA1 vs. SZ CA2/3) or
diagnostic group (i.e., SZ CA1 vs. CON CA1) comparison, and the mean delta beta and mean FDR for all DMPs in
that comparison. At the bottom is the overlap of specific CpG sites among the various comparisons, with # of DMPs
indicating the number of DMPositions that are common to the two listed comparisons (i.e., SZ vs. BD indicates
there are 107 DMPositions common to both the SZ CA1 vs. SZ CA2/3 and the BD CA1 vs. BD CA2/3 comparisons).
All three groups indicate there are 46 DMPositions common to all three within diagnostic subgroup comparisons.
% of DMPs lists the percentage of DMPositions from the comparison with the smaller number of DMPositions that
are common to both indicated comparisons (i.e., for SZ vs. BD 107 common DMPositions/201 BD CA1 vs. BD
CA2/3 DMPositions = 53.23%). DMP: differentially methylated position; FDR: false detection rate.
3.2. Differentially Methylated Regions
Investigation of DMRegions yielded similar results, with zero significant DMRegions detected in
any of the four between-diagnosis comparisons described above, and multiple DMRegions between
each circuit location within diagnostic subgroups. Figure 2a shows the 19 significant DMRegions
between SZ CA1 and SZ CA2/3, 23 DMRegions between BD CA1 and BD CA2/3, and ten DMRegions
between CON CA1 and CON CA2/3, and shown in Figure 2b are the 103 significant DMRegions
between CA1 and CA2/3 in all cases, pooled without consideration of diagnosis. As with DMPositions,
there is a large amount of overlap of circuit location of DMRegions between the diagnostic subgroups
(Table 3), with approximately half as many DMRegions observed in the control subjects as there were
in each of the patient groups.
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Figure 2. Differentially Methylated Regions ( egions). (a) Similar to Figure 1a, shown are the
DMRegions identified within each eight-case diagnostic subgroup comparison (19 in SZ CA1 vs. SZ
CA2/3, 23 in BD CA1 vs. BD CA2/3, 10 in CON CA1 vs. CON CA2/3), with the X axis again
depicting the space corresponding to the 5476 HM450 probes assessing sites within the 128 PGC
regions, and the Y axis depicting the −log10 (Stouffer corrected p-value) of each DMRegion. X-axis
ticks mark the boundaries between PGC regions. Dashed vertical lines indicate the locations of
BD-associated DMRegions (the most abundant) to demonstrat the scarcity of DMRegions that are
not shared across comparisons within th separate diagnostic subgroups; (b) The 103 DMRegions
identified in comparison of all 24 CA1 samples vs. all 24 CA2/3 samples are plotted against the same
axes as Figure 2a.
Table 3. Distribution and overlap of differentially methylated regions among circuit
location comparisons.
Chr Start End Description SZ BD CON Pooled
chr01 2381300 2381623 26 kb upstream of PLCH2 13 28
chr01 2391242 2391347 16 kb upstream of PLCH2 16
chr01 8484005 8484417 RERE intron 12 18 24
chr01 150123038 150123734 PLEKH01 spans exon 2 3 5 5 21
chr01 150229144 150230345 CA14 TSS 3 10 9
chr01 243584669 243584861 SDCC G8 intron #15 1 1 6 8
chr02 72357938 72358024 CYP26B1 3′ e d 4 4 3 6
chr03 2553086 2553187 CNTN4 intron 3 11 39
chr06 28499677 28499 2 GPX5 exon 3 3′ boundary 8 83
chr07 1983170 1983503 MA L1 intr 6 7 18
chr07 214350 21 4767 MA L1 intr 12 17 17
chr07 86413439 8641 302 GRM3 intr 2 23 40
chr07 104909 31 104909815 SRPK2 exon 3 5′ boundary 19 45
chr10 18689036 18689503 CACNB2 exon 5 5′ boundary 8 14 16
chr11 46365894 46367100 DGKZ exon 1 2 13 1
chr11 46383032 46383209 DGKZ exon 4 22 14
chr11 46401423 46401447 DGKZ exon 32 19 47
chr11 57414402 57414908 YPEL4 spans exon 2 5 8 7
chr12 57589254 57589740 LRP1 exon 53 16 29
chr12 57597137 57597238 LRP1 exon 70 5′ boundary 10 10 4 19
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Table 3. Cont.
Chr Start End Description SZ BD CON Pooled
chr14 104171260 104172224 XRCC3 intron 6 15 2
chr15 40599681 40600635 PLCB2 TSS 6 12
chr15 91426668 91427884 Overlaps FURIN 3′ end & FES TSS 20 9 4
chr16 30124804 30124904 GDPD3 3′ end 21 36
chr16 67918485 67919362 NRN1L TSS 15 6 10
chr16 67977866 67978450 SLC12A4 exon 24 11 2 2 3
chr16 68000764 68001415 CLC12A4 exon 2 5′ boundary 17 20
chr17 18011514 18012134 MYO15A TSS 12 12 13
chr20 37464180 37464594 PPP1R16B exon 2 14 7 1 5
chr22 41613693 41613790 L3MBTL2 intron 5 9 23
chr22 41636942 41637617 CHADL TSS 9 18 11
chr22 42347907 42348061 LINC00634 TSS 7 35
Listed are the locations of all DMRegions identified in the three within-diagnosis comparisons of CA1 and CA2/3.
Numbers depict the rank order of that DMRegion in the indicated comparison, and missing numbers indicate that
the associated region was not detected as significantly differentially methylated in that comparison.
4. Discussion
As our understanding of the complex structure of genetic risk for schizophrenia advances,
an important next step in understanding this disease will be the difficult task of mapping that
structure onto the complex neural circuitry of the human brain. Even in unicellular organisms,
the relation between genotype and phenotype is highly complicated, as a given mutation informs
phenotype through a set of modifiers within the genetic background that are specific to an individual
organism [17,18]. Considering this single-cell complexity in concert with the extraordinary diversity
of neuronal and glial cell types and circuits within the human brain, a robust understanding of
how a genotype is elaborated into the unique phenotypes within the many cells that comprise the
complex circuits found within individual cortical layers, regions, and subregions presents a formidable
challenge both in health and in disease states such as schizophrenia.
Within the 108 PGC schizophrenia-associated genomic regions, we observed only a single
DMPosition in all four of the diagnostic comparisons, as opposed to 497 DMPositions in the three circuit
location-based comparisons. Similarly, there were no DMRegions identified in the four diagnostic
comparisons, and a total of 52 DMRegions across all three circuit location comparisons. This finding
of greater differences in DNA methylation patterns between brain regions from the same individual
than exist within a single brain region across separate subjects is in keeping with previous work [8],
and to our knowledge these data represent the most subtle comparison yet made. Interestingly, a more
recent study [19] drew the exact opposite conclusion, finding that methylation differs more between
individuals than between brain regions (with the exception of cerebellum compared to cerebral cortical
regions). While the cause of this disagreement is unknown, multiple technical differences between the
studies (Methylated DNA Immunoprecipitation Sequencing vs. MBD Affinity Purification Sequencing,
distinct brain regions sampled, and different analytic techniques) may have contributed.
These data are consistent with another recently published study that investigated
schizophrenia-associated DNA methylation changes across four distinct regions of the human brain in
homogenized whole cortex, accounting for estimates of neuronal/glial proportions in each sample [20].
The prior study found multiple DMPositions and DMRegions between schizophrenia and control
subjects, and while many were shared across brain regions, the majority of these changes were
significant in only a subset of regions, with the cerebellum being the most distinct region assayed.
In alignment with our findings, the prior study found no enrichment of schizophrenia-associated
DMPositions or DMRegions within the 108 PGC regions. Very interestingly, this prior work found the
association of DNA methylation with a schizophrenia polygenic risk score based on the PGC GWAS
results to be much more consistent across brain regions than was the association of DNA methylation
with a formal diagnosis of schizophrenia.
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As detailed in Table 2, the average methylation change for all DMPs observed in our analysis
was 4.5%, a value in keeping with many methylation change findings published from similar
investigations [12,20,21]. The potential functional impact of a change of this magnitude within a
complex heterogenous system such as the human hippocampus is difficult to predict and likely
dependent on a great many factors, including the specific genomic context of each cytosine residue
in question. While our laser-microdissected samples contain a more homogenous population of cells
than samples of homogenized brain structures, they are still composed of multiple distinct cell types
(i.e., glia and multiple GABAergic interneuronal cell types). Methylation changes are certainly not
evenly distributed among all cells assessed by our measurements, and as such some populations are
likely to host greater methylation differences between circuit locations and some populations lesser
differences. As technologies continue to allow for the assessment of increasingly homogenous neuronal
populations, effect sizes of identified disease and circuit location-associated methylation changes will
likely increase. Another point in consideration of the functional importance of these differences is
that the field is currently elucidating multiple roles for DNA methylation beyond the direct regulation
of gene expression, including the regulation of alternate promoter usage, alternative splicing events,
and support of transcriptional elongation [22].
While the samples employed here are far more specific than homogenized whole cortex, which
is the most common method used to investigate human brain tissue, it is still essential to account
for possible shifts in cellular populations between samples. The stratum oriens of the hippocampus
contains exclusively GABAergic interneurons in addition to glial cells [14,23]. There exist tools
to estimate the proportion of neuronal and non-neuronal cells within a sample based on its DNA
methylation profile (i.e., the estimateCellCounts function within the minfi Bioconductor package [15]),
however, these tools require a preexisting DNA methylation dataset from fluorescence-activated
cell sorted (FACS) tissue. No such dataset is available for stratum oriens tissue from the human
hippocampus, and available datasets from FACS sorted homogenized whole cortex are not applicable
to our data. Previous work in our lab assessing gene expression profiles in equivalently microdissected
stratum oriens tissue from CA1 and CA3 in a non-overlapping cohort of postmortem human
hippocampus [24] found no significant difference between circuit locations in the expression of the
glial specific mRNA marker GFAP (encoding glial fibrilary acidic protein) or the neuron specific mRNA
ENO2 (encoding enolase 2, also known as neuron specific enolase) as normalized to the expression
of the housekeeping gene GAPDH (encoding glyceraldehyde 3-phosphate dehydrogenase). Based
on these findings, we are confident that the reported DNA methylation changes between the stratum
oriens of CA1 and CA3 are not due to different proportions of neurons and glia present at these
circuit locations, but instead depict distinct methylation profiles within phenotypically equivalent
cellular populations.
The present analyses included a relatively small cohort, and greater numbers may have identified
additional DMPositions or DMRegions, but the general observation of more between circuit location
differences than between-subject differences is still valid. Additionally, the lack of genotyping data for
the subjects precluded searching for meQTLs within the PGC regions in our cohort, as others have
done previously [11,12]. One further potential limitation of this study is our inability to investigate
CpG sites within the PGC regions not targeted by probes on the HM450 BeadArray. Indeed, there
are 25 PGC regions associated with zero HM450 probes, and another 14 regions associated with only
a single probe. Again, these shortcomings do not undermine conclusions regarding the within vs.
between-subject comparisons described above.
While patients within the SZ and BD groups were treated with psychotropic medications [13],
we argue that medication is not driving the observed changes in DNA methylation for two reasons.
First, we observed more DNA methylation differences within between-circuit comparisons, where
medication exposure is perfectly balanced as the same individuals are present in the CA1 group
and the CA2/3 group, as opposed to comparisons across diagnostic groups of separate individuals.
Second, there is a large degree of overlap in DMPositions and DMRegions found in the three diagnostic
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groups, including the non-medication exposed control group. We cannot exclude the possibility
that medication exposure is causal of the twofold greater numbers of DMPositions and DMRegions
observed in the SZ and BD groups as compared to the CON group, and this greater difference across
circuit locations in psychotic disorders as a result of either the disease process itself or its pharmacologic
treatment is an interesting finding requiring further study.
5. Conclusions
Even as basic a molecular phenotype as DNA methylation patterns shows variation across closely
related cellular populations such as those found within a single cellular layer in distinct subfields of
the human hippocampus within individual subjects. The 108 PGC schizophrenia-associated genomic
regions represent a subset of the genome where inter-individual genetic variation is likely to be
especially relevant to an individual’s risk for schizophrenia. Our finding of greater differences in
DNA methylation of these regions between circuit locations within the identical genetic background of
the same individuals as compared to the differences between genetically diverse groups of patients
and controls illustrates the difficulties of determining the impact of a given genotype on the complex
phenotypes encompassed by a neuropsychiatric illness such as schizophrenia. Understanding the
influence of genetic variants on the complex landscape of schizophrenia risk within the many distinct
cell types, circuits, tissue microenvironments, and time points relevant to this disease is the next
necessary step in this ongoing and grand challenge.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/8/5/143/s1.
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